Neogenomics Inc Stock Price, News & Analysis

NeoGenomics (NASDAQ: NEO) will present new circulating tumor DNA (ctDNA) data from its RaDaR 1.0 assay at the 2025 San Antonio Breast Cancer Symposium (Dec 9–12, 2025).

Presentations include 5-year CLEVER follow-up data showing RaDaR-detected ctDNA was present in most patients with disseminated tumor cells and frequently preceded clinical recurrence by months, plus interim results from the SURVIVE and SURVIVE HERoes Phase III trials evaluating liquid-biopsy guided follow-up and earlier intervention at molecular relapse.

NeoGenomics (NASDAQ: NEO) will present a real-world study at the 67th ASH Annual Meeting (Dec 6–9, 2025) showing that comprehensive genomic profiling (CGP) using the Neo Comprehensive Myeloid panel can refine diagnosis and inform treatment in myeloid malignancies.

Researchers analyzed 533 patients, integrating molecular results with national clinical data; CGP identified pathogenic changes earlier in about one-third of patients and revealed rare actionable fusions (PDGFRA, PDGFRB, FGFR1, JAK2) that guided targeted therapy decisions. The poster is scheduled for Dec 8, 2025, 6:00–8:00 PM ET in session 908A; attendees can visit Booth #1971 for more information.

NeoGenomics (NASDAQ:NEO) will participate in two investor conferences in late 2025: a company presentation at the Stephens Annual Investment Conference in Nashville on Wednesday, November 19, 2025 at 1:00 pm CT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025 at 2:30 pm ET.

Both sessions will offer live and archived webcasts available on the company’s Investor Relations site at ir.neogenomics.com.

NeoGenomics (NASDAQ: NEO) will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 assays for molecular residual disease (MRD) detection across solid tumors.

The bridging study evaluated matched samples from 166 patients across 15 solid tumor types, reporting 97% concordance and equivalent sensitivity for RaDaR ST versus RaDaR 1.0. RaDaR ST currently has Medicare coverage for HR+/HER2- breast cancer (recurrence monitoring >5 years after diagnosis) and HPV- head and neck carcinoma (adjuvant and recurrence monitoring). NeoGenomics expects the launch of RaDaR ST in Q1 2026 and will also present additional posters on whole genome–informed MRD, PanTracer LBx validation, and genomic profiling at ISLB 2025.

NeoGenomics (NASDAQ: NEO) reported third quarter 2025 results for the period ended September 30, 2025. Consolidated revenue rose 12% YoY to $188 million, driven by clinical revenue +18% and NGS revenue +24%, with NGS representing nearly one-third of clinical revenue. Revenue per clinical test increased 3% to $476. Net loss widened 53% to $27 million and Adjusted EBITDA fell 9% to $12.2 million. Cash and marketable securities totaled $164 million. The company re-affirmed full-year 2025 guidance of $720–$726 million revenue and retained its prior adjusted EBITDA and net loss ranges.

NeoGenomics (NASDAQ: NEO) will highlight its RaDaR ST molecular residual disease (MRD) circulating tumor DNA assay at the ESMO Congress 2025, October 17–21 in Berlin.

The company said RaDaR ST uses whole-exome sequencing from tumor samples plus advanced bioinformatics to create patient-specific MRD panels, applying high-depth sequencing and personalized design to sensitively detect ctDNA in plasma and track tumor dynamics and treatment response. NeoGenomics will present three new posters from European collaborators, note interventional therapy trials in progress, and feature RaDaR ST and broader oncology testing at booth #4012.

NeoGenomics (NASDAQ: NEO) will report third quarter 2025 financial results before U.S. market open on Tuesday, October 28, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to discuss results and recent highlights.

Investors can access the live webcast via the company's Investor Relations site at ir.neogenomics.com. The webcast will be archived and available for replay. To join by phone, dial (888) 506-0062 (U.S.) or (973) 528-0011 (international) and use participant code 392611.

NeoGenomics (NASDAQ:NEO) has secured a significant legal victory as the District Court for the Middle District of North Carolina granted summary judgment in its patent infringement lawsuit against Natera. The Court ruled that Natera's asserted patent claims are invalid for claiming ineligible subject matter.

This ruling allows NeoGenomics to freely commercialize its RaDaR ST molecular residual disease (MRD) assay in the United States. The company has already launched RaDaR ST to biopharma customers and has submitted for clinical reimbursement coverage through CMS's MolDX program.

NeoGenomics (NASDAQ: NEO) has launched NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test designed for advanced solid tumors. The new test analyzes over 500 genes, including MSI and bTMB markers, with a 7-day turnaround time.

PanTracer LBx enables therapy selection, trial matching, and disease monitoring through a simple blood draw when tissue samples are limited or unavailable. This strategic launch positions NeoGenomics in the $3-5 billion liquid biopsy market, complementing their existing tissue-based testing portfolio and expanding their addressable market.